The cytokine interferon-gamma (IFN-g) is another candidate therapeutic agent for the treatment of TSC because the presence of a high-expressing IFN-g allele has been linked to significantly reduced kidney tumor burdens in Tsc2+/- mice relative to the tumor burden in the kidneys of Tsc2+/- mice with normal IFN-g levels [35]. This evidence concerns the gene IFNG and kidney neoplasm.